Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


1 Am J Clin Oncol
2 Am J Clin Pathol
1 Ann Oncol
1 Arch Bronconeumol
8 Arch Bronconeumol (Engl Ed)
1 BMC Cancer
2 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Cancer Res
1 Cancer Sci
1 Clin Cancer Res
1 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cancer
3 Eur J Cardiothorac Surg
1 Int J Cancer
3 Int J Radiat Oncol Biol Phys
1 J Thorac Cardiovasc Surg
2 J Thorac Oncol
1 JAMA Oncol
73 Lung Cancer
2 Mol Cancer Ther
1 Oncogene
1 Oncol Rep
7 Oncologist
5 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Oncol

  1. YANG W, Zhang Y, Xia D, Xu X, et al
    The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
    Am J Clin Oncol. 2021;44:224-225.

    Am J Clin Pathol

  2. CHATZOPOULOS K, Johnson TF, Boland JM
    Clinical, Radiologic, and Pathologic Characteristics of Pulmonary Hamartomas With Uncommon Presentation.
    Am J Clin Pathol. 2021;155:903-911.
    PubMed         Abstract available

  3. SHIRSAT H, Zhou F, Chang JC, Rekhtman N, et al
    Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor.
    Am J Clin Pathol. 2021;155:832-844.
    PubMed         Abstract available

    Ann Oncol

  4. SUGAWARA S, Lee JS, Kang JH, Kim HR, et al
    Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ann Oncol. 2021 Jun 14. pii: S0923-7534(21)02052.
    PubMed         Abstract available

    Arch Bronconeumol

  5. LAINEZ RAMOS-BOSSINI AJ, Perez Garcia MDC, Rueda Caceres MT
    Pneumomediastinum and Massive Subcutaneous Emphysema Due to Lung Neoplasm.
    Arch Bronconeumol. 2019 Jul 30. pii: S0300-2896(19)30288.

    Arch Bronconeumol (Engl Ed)

    Recurrent Spontaneous Pneumothorax Due to Pulmonary Cystic Metastasis of Epithelioid Sarcoma.
    Arch Bronconeumol (Engl Ed). 2021;57:368.

  7. CONCEICAO M, Cunha AD, Reis A
    Black Bronchoscopy in the Diagnosis of a Lung Mass.
    Arch Bronconeumol (Engl Ed). 2021;57:303.

  8. TANG J, Curull V, Ramis-Cabrer D, Duran X, et al
    Preoperative Body Weight and Albumin Predict Survival in Patients With Resectable Lung Neoplasms: Role of COPD.
    Arch Bronconeumol (Engl Ed). 2021;57:51-60.
    PubMed         Abstract available

  9. MARTINEZ-PALAU M, Trujillo-Reyes JC, Jaen A, Call S, et al
    How do we Classify a Central Tumor? Results of a Multidisciplinary Survey from the SEPAR Thoracic Oncology Area.
    Arch Bronconeumol (Engl Ed). 2021;57:359-365.
    PubMed         Abstract available

  10. ESPINOSA V, Bologna I, Bernasconi M
    Endobronchial Papillomatosis of the Central Airways.
    Arch Bronconeumol (Engl Ed). 2021;57:371.

  11. RUIZ-ALVAREZ I, Gutierrez Palacios AM, Rodriguez Diaz B
    Pulmonary Nodular Amyloidosis. A Rare Cause of Multiple Pulmonary Nodules.
    Arch Bronconeumol (Engl Ed). 2021;57:227.

  12. TAUS A, Camacho L, Rocha P, Hernandez A, et al
    Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
    Arch Bronconeumol (Engl Ed). 2021;57:323-329.
    PubMed         Abstract available

  13. JUANOLA-PLA J, Tomas MC, Castillo MPO
    Sclerosing Pneumocytoma Presenting as Endobronchial Tumor With Negative Autofluorescence.
    Arch Bronconeumol (Engl Ed). 2021;57:300.

    BMC Cancer

  14. RUSMAULLY J, Tvardik N, Martin D, Billmann R, et al
    Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).
    BMC Cancer. 2021;21:711.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  15. YU S, Li Y, Ren H, Zhou H, et al
    PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.
    Cancer Chemother Pharmacol. 2021;87:207-215.
    PubMed         Abstract available

  16. CINIERO G, Elmenoufy AH, Gentile F, Weinfeld M, et al
    Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Cancer Chemother Pharmacol. 2021;87:259-267.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  17. WOOD AM, Jonsson H, Nagel G, Haggstrom C, et al
    The inverse association of body mass index with lung cancer: exploring residual confounding, metabolic aberrations and within-person variability in smoking.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 22. pii: 1055-9965.EPI-21-0058.
    PubMed         Abstract available

    Cancer Lett

  18. TRAVER G, Sekhar KR, Crooks PA, Keeney DS, et al
    Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
    Cancer Lett. 2021;500:220-227.
    PubMed         Abstract available

    Cancer Res

  19. LI HJ, Ke FY, Lin CC, Lu MY, et al
    ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-mesenchymal transition.
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3543.
    PubMed         Abstract available

    Cancer Sci

  20. FUKUDA K, Otani S, Takeuchi S, Arai S, et al
    Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Cancer Sci. 2021 Jun 19. doi: 10.1111/cas.15035.
    PubMed         Abstract available

    Clin Cancer Res

  21. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed         Abstract available

    Clin Lung Cancer

  22. RIESS JW, Reckamp KL, Frankel P, Longmate J, et al
    Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Clin Lung Cancer. 2021 May 15. pii: S1525-7304(21)00094.
    PubMed         Abstract available

    Clin Nucl Med

  23. LIU BL, Hong JJ, Tang K, Lin J, et al
    18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.
    Clin Nucl Med. 2021;46:e355-e357.
    PubMed         Abstract available

    Eur J Cancer

  24. CANTINI L, Pecci F, Dammeijer F, Aerts JGJV, et al
    Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 Jun 18. pii: S0959-8049(21)00325.

    Eur J Cardiothorac Surg

  25. NA KJ, Park S, Lee HJ, Park IK, et al
    Comparison between lung perfusion scan and single-photon emission computed tomography/computed tomography for predicting postoperative lung function after pulmonary resection in patients with borderline lung function.
    Eur J Cardiothorac Surg. 2020 Sep 3. pii: 5900864. doi: 10.1093.
    PubMed         Abstract available

  26. CHEN C, Zhang X, Gu C, Wang Y, et al
    Surgery performed at night by continuously working surgeons contributes to a higher incidence of intraoperative complications in video-assisted thoracoscopic pulmonary resection: a large monocentric retrospective study.
    Eur J Cardiothorac Surg. 2019 Sep 20. pii: 5572143. doi: 10.1093.
    PubMed         Abstract available

  27. PETERSEN RH, Huang L, Kehlet H
    Guidelines for enhanced recovery after lung surgery: need for re-analysis.
    Eur J Cardiothorac Surg. 2021;59:291-292.

    Int J Cancer

  28. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  29. NGUYEN C, Dietz N
    Lung Mass With Massive Hemoptysis: Treatment Without Tissue Diagnosis.
    Int J Radiat Oncol Biol Phys. 2021;109:5-6.

  30. DE BARI B
    Cautious SBRT.
    Int J Radiat Oncol Biol Phys. 2021;109:315.

  31. DUNNE EM, Liu M
    Postoperative Stereotactic Body Radiation Therapy, Then Observe.
    Int J Radiat Oncol Biol Phys. 2021;109:316.

    J Thorac Cardiovasc Surg

  32. ISBELL JM, Li BT, Gomez DR
    The emerging role of local therapy in oligometastatic non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 May 29. pii: S0022-5223(21)00875.

    J Thorac Oncol

  33. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.

  34. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    PubMed         Abstract available

    JAMA Oncol

  35. HUI Z, Men Y, Hu C, Kang J, et al
    Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
    PubMed         Abstract available

    Lung Cancer

  36. CHIA PL, Parakh S, Russell P, Gan HK, et al
    Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
    Lung Cancer. 2021;153:35-41.
    PubMed         Abstract available

  37. AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
    Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Lung Cancer. 2021;153:56-65.
    PubMed         Abstract available

  38. ZHOU F, Huang Y, Cai W, Li J, et al
    The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Lung Cancer. 2021;153:66-72.
    PubMed         Abstract available

  39. LIU Y, Gao GF, Minna JD, Williams NS, et al
    Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
    Lung Cancer. 2021;153:73-80.
    PubMed         Abstract available

  40. DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
    RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
    Lung Cancer. 2021;153:90-98.
    PubMed         Abstract available

  41. REN P, Luo N, Qi Y, Wu Y, et al
    A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Lung Cancer. 2021;153:179-181.

  42. WANG B, Chen R, Wang C, Chen H, et al
    PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:176-178.

  43. ZHAI X, Wu Q, Zeng Z, Suo J, et al
    OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:171-173.

  44. MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
    Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
    Lung Cancer. 2021;153:117-119.
    PubMed         Abstract available

  45. LI R, Jiang L, Zhou X, Lu Y, et al
    Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
    Lung Cancer. 2021;153:120-125.
    PubMed         Abstract available

  46. FUCHS V, Roisman L, Kian W, Daniel L, et al
    The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Lung Cancer. 2021;153:126-133.
    PubMed         Abstract available

  47. ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
    Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
    Lung Cancer. 2021;153:158-164.
    PubMed         Abstract available

  48. BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
    Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
    Lung Cancer. 2021;153:182-183.

  49. CAI C, Tang Y, Li Y, Chen Y, et al
    Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Lung Cancer. 2021;152:104-108.
    PubMed         Abstract available

  50. SUZUKI J, Aokage K, Neri S, Sakai T, et al
    Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Lung Cancer. 2021;153:1-10.
    PubMed         Abstract available

  51. LI X, Liu J, Guo M, Cai H, et al
    NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
    Lung Cancer. 2021;152:202-204.

  52. GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
    Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
    Lung Cancer. 2021;152:1-6.
    PubMed         Abstract available

  53. KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
    Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
    Lung Cancer. 2021;152:15-20.
    PubMed         Abstract available

  54. CHAE M, Jeon JH, Chung JH, Lee SY, et al
    Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
    Lung Cancer. 2021;152:21-26.
    PubMed         Abstract available

  55. BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
    CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
    Lung Cancer. 2021;152:34-38.
    PubMed         Abstract available

  56. GENDARME S, Matton L, Antoine M, Kerrou K, et al
    Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
    Lung Cancer. 2021;152:94-97.
    PubMed         Abstract available

  57. BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
    Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Lung Cancer. 2021;152:119-126.
    PubMed         Abstract available

  58. MA H, Zhang Q, Duan Q, Zhang Q, et al
    Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Lung Cancer. 2021;152:196-198.

  59. LIANG P, Qi L, Guo T, You X, et al
    A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Lung Cancer. 2021;152:193-195.

  60. HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
    Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Lung Cancer. 2021;152:135-142.
    PubMed         Abstract available

  61. MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
    Subclinical myasthenia gravis in thymomas.
    Lung Cancer. 2021;152:143-148.
    PubMed         Abstract available

  62. ZHAO G, Chen L, Xiao M, Yang S, et al
    Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Lung Cancer. 2021;152:189-192.

  63. LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
    Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
    Lung Cancer. 2021;152:157-164.
    PubMed         Abstract available

  64. KUNIMASA K, Oka T, Hara S, Yamada N, et al
    Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
    Lung Cancer. 2021;153:186-192.
    PubMed         Abstract available

  65. PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
    Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
    Lung Cancer. 2021;154:186-194.
    PubMed         Abstract available

  66. KIM HW, Kim JS, Lee SH
    Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Lung Cancer. 2021;158:107-114.
    PubMed         Abstract available

  67. SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
    High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2021;157:1-8.
    PubMed         Abstract available

  68. GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
    LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2021;156:129-135.
    PubMed         Abstract available

  69. LAROSE F, Quigley N, Lacasse Y, Martel S, et al
    Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
    Lung Cancer. 2021;156:151-156.
    PubMed         Abstract available

  70. PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
    Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
    Lung Cancer. 2021;156:117-121.
    PubMed         Abstract available

  71. SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
    Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
    Lung Cancer. 2021;156:109-116.
    PubMed         Abstract available

  72. LAU SCM, Poletes C, Le LW, Mackay KM, et al
    Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lung Cancer. 2021;156:76-81.
    PubMed         Abstract available

  73. NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
    A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
    Lung Cancer. 2021;156:1-4.
    PubMed         Abstract available

  74. HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
    Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Lung Cancer. 2021;155:175-182.
    PubMed         Abstract available

  75. JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
    Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
    Lung Cancer. 2021;156:147-150.
    PubMed         Abstract available

  76. CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
    A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
    Lung Cancer. 2021;157:165-166.

  77. CHINTALA NK, Restle D, Quach H, Saini J, et al
    CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
    Lung Cancer. 2021;157:48-59.
    PubMed         Abstract available

  78. CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
    Lymph Node Dissection in Thymoma: Is it worth it?
    Lung Cancer. 2021;157:156-162.
    PubMed         Abstract available

  79. XIE XJ, Liu SY, Chen JY, Zhao Y, et al
    Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Lung Cancer. 2021;157:30-39.
    PubMed         Abstract available

  80. TALCOTT WJ, Miccio JA, Park HS, White AA, et al
    Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
    Lung Cancer. 2021;157:17-20.
    PubMed         Abstract available

  81. ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
    Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Lung Cancer. 2021;157:147-155.
    PubMed         Abstract available

  82. LESIRE B, Durieux V, Grigoriu B, Girard N, et al
    Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
    Lung Cancer. 2021;157:131-146.
    PubMed         Abstract available

  83. YANG Y, Ran J, Wang Y, Zhou Z, et al
    Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
    Lung Cancer. 2021;157:116-123.
    PubMed         Abstract available

  84. PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
    Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
    Lung Cancer. 2021;157:85-91.
    PubMed         Abstract available

  85. BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
    Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
    Lung Cancer. 2021;157:79-84.
    PubMed         Abstract available

  86. SUMI T, Nakata H, Chiba H
    Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
    Lung Cancer. 2021;155:196-198.

  87. LUO Y, Wei J, Zhang J, Zeng L, et al
    Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Lung Cancer. 2021;155:170-174.
    PubMed         Abstract available

  88. NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
    Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2021;155:163-169.
    PubMed         Abstract available

  89. WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
    Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Lung Cancer. 2021;154:216-218.

  90. ZHANG C, Wang H
    Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
    Lung Cancer. 2021;154:221-223.

  91. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Lung Cancer. 2021;154:92-98.
    PubMed         Abstract available

  92. ZHANG C, Wang H
    The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
    Lung Cancer. 2021;154:214-215.

  93. WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
    Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
    Lung Cancer. 2021;154:76-83.
    PubMed         Abstract available

  94. LI Z, Li F, Pan C, He Z, et al
    Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
    Lung Cancer. 2021;154:69-75.
    PubMed         Abstract available

  95. COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
    Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
    Lung Cancer. 2021;154:23-28.
    PubMed         Abstract available

  96. KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
    Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Lung Cancer. 2021;154:5-12.
    PubMed         Abstract available

  97. ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
    Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
    Lung Cancer. 2021;155:183-190.
    PubMed         Abstract available

  98. SHANG X, Li Z, Sun J, Zhao C, et al
    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Lung Cancer. 2021;154:105-112.
    PubMed         Abstract available

  99. XIONG A, Li C, Xu J, Yang X, et al
    Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Lung Cancer. 2021;154:124-130.
    PubMed         Abstract available

  100. VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
    Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
    Lung Cancer. 2021;155:156-162.
    PubMed         Abstract available

  101. LV W, Wang Y, Zhou C, Yuan M, et al
    Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
    Lung Cancer. 2021;155:78-86.
    PubMed         Abstract available

  102. ZHAO D, Hou F, Li M, Qi Y, et al
    A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
    Lung Cancer. 2021;155:193-195.

  103. MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
    Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Lung Cancer. 2021;155:10-19.
    PubMed         Abstract available

  104. FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
    Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
    Lung Cancer. 2021;155:1-9.
    PubMed         Abstract available

  105. BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
    Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
    Lung Cancer. 2021;157:163-164.

  106. YANG L, Zhao W, Zhu H, Li X, et al
    PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;154:219-220.

  107. COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
    Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
    Lung Cancer. 2021;154:146-150.
    PubMed         Abstract available

  108. VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
    Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Lung Cancer. 2021;154:131-141.
    PubMed         Abstract available

    Mol Cancer Ther

  109. KANO H, Ichihara E, Watanabe H, Nishii K, et al
    SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
    PubMed         Abstract available

  110. ZHANG D, Hou Z, Aldrich KE, Lockwood L, et al
    A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-21-0210.
    PubMed         Abstract available


  111. LIANG SK, Hsu CC, Song HL, Huang YC, et al
    FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01895.
    PubMed         Abstract available

    Oncol Rep

  112. LIN CC, Liao WT, Yang TY, Lu HJ, et al
    MicroRNA10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed         Abstract available


  113. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    PubMed         Abstract available

  114. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    PubMed         Abstract available

  115. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    PubMed         Abstract available

  116. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    PubMed         Abstract available

  117. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    PubMed         Abstract available

  118. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.

  119. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    PubMed         Abstract available

    PLoS One

  120. NG WW, Lin CC, Cheng CY, Jiang JS, et al
    Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    PLoS One. 2021;16:e0253335.
    PubMed         Abstract available

  121. IKAWA T, Tabuchi T, Konishi K, Morimoto M, et al
    Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis.
    PLoS One. 2021;16:e0253203.
    PubMed         Abstract available

  122. WRIGHT GM, Gimbrone NT, Sarcar B, Percy TR, et al
    CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    PLoS One. 2021;16:e0252927.
    PubMed         Abstract available

  123. CHUNG HS, Bae S, Kim I, Ahn HY, et al
    Unexpected exposure to Mycobacterium tuberculosis during bronchoscopy using radial probe endobronchial ultrasound.
    PLoS One. 2021;16:e0246371.
    PubMed         Abstract available

  124. TSAKANOVA G, Stepanyan A, Arakelova E, Ayvazyan V, et al
    The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro.
    PLoS One. 2021;16:e0253553.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  125. JIMENEZ-SANCHEZ J, Bosque JJ, Jimenez Londono GA, Molina-Garcia D, et al
    Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.